| __timestamp | Geron Corporation | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 16758000 | 11606000000 |
| Thursday, January 1, 2015 | 17793000 | 10313000000 |
| Friday, January 1, 2016 | 18761000 | 9762000000 |
| Sunday, January 1, 2017 | 19287000 | 9830000000 |
| Monday, January 1, 2018 | 18707000 | 10102000000 |
| Tuesday, January 1, 2019 | 20893000 | 10615000000 |
| Wednesday, January 1, 2020 | 25678000 | 8955000000 |
| Friday, January 1, 2021 | 29665000 | 9634000000 |
| Saturday, January 1, 2022 | 43628000 | 10042000000 |
| Sunday, January 1, 2023 | 69135000 | 10504000000 |
Data in motion
In the ever-evolving pharmaceutical industry, operational efficiency is key. Over the past decade, Merck & Co., Inc. and Geron Corporation have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. While Merck's SG&A expenses have remained relatively stable, averaging around $10 billion annually, Geron has seen a significant increase, with expenses rising by over 300% from 2014 to 2023. This divergence highlights Merck's consistent operational scale compared to Geron's aggressive expansion strategy. Notably, in 2023, Geron's SG&A expenses surged to nearly $69 million, reflecting its commitment to growth. As the pharmaceutical landscape continues to shift, these financial strategies offer a glimpse into the companies' future directions and market positioning.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Merck & Co., Inc.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Novartis AG
Merck & Co., Inc. vs Regeneron Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Merck & Co., Inc. vs Merus N.V. Trends and Insights
Merck & Co., Inc. or Geron Corporation: Who Leads in Yearly Revenue?
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Evotec SE Trends and Insights
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Geron Corporation Trends and Insights
BioMarin Pharmaceutical Inc. vs Geron Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and Geron Corporation
Cost Management Insights: SG&A Expenses for ACADIA Pharmaceuticals Inc. and Geron Corporation
Cost Management Insights: SG&A Expenses for MorphoSys AG and Geron Corporation